Immunology
Researchers tie Lebrikizumab to sustained atopic dermatitis treatment effect
Lebrikizumab is associated with sustained effects for moderate-to-severe atopic dermatitis for up to week 52 following withdrawal of treatment, according to a study presented at the annual Revolutionizing Atopic Dermatitis ...
Jun 18, 2024
0
0